Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca And Abbott Pull The Plug On Cardio Combination Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Saying it was no longer commercially attractive, the partners ended development of mixed dyslipidemia treatment Certriad, a pill that combines a statin and a fibrate, due to the FDA's "complete response" received earlier this year.
Advertisement

Related Content

New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials
Abbott Refreshes Rheumatoid Arthritis Strategy By Licensing Biotest's Phase II Candidate
Abbott Refreshes Rheumatoid Arthritis Strategy By Licensing Biotest's Phase II Candidate
Abbott Shaves U.S. Pharma Costs With Restructuring
Abbott Shaves U.S. Pharma Costs With Restructuring
Abbott/AstraZeneca's Certriad Bounced By FDA; ACCORD May Be The Culprit
AstraZeneca To Co-Promote Abbott’s TriLipix; NDA Is Filed For Crestor/TriLipix
AstraZeneca To Co-Promote Abbott’s TriLipix; NDA Is Filed For Crestor/TriLipix

Topics

Advertisement
UsernamePublicRestriction

Register

PS071654

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel